Compare Alcon AG (ALC) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Nomura Holdings Inc — how do they compare? Alcon AG trades at $66.88 (market cap $32.69B), while Nomura Holdings Inc trades at $9.41 (market cap $27.73B). The key difference: Alcon AG is the larger of the two by market cap, and Nomura Holdings Inc pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| ALC | NMR | |
|---|---|---|
Market Cap | $32.69B | $27.73B |
Sector | Health | Financials |
52-Week High | $92.22 | $9.54 |
52-Week Low | $62.02 | $6.30 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Nomura Holdings (NMR) trades at $9.42, up 3.97% with a bullish technical signal. The stock shows strong fundamentals with record annual profit of $340.74B (20.49% margin) and revenue growth to $1.66T. Recent news highlights CEO pay increase following record performance and US expansion plans. Technical indicators show bullish momentum with RSI at neutral levels, while analyst consensus leans hold-heavy with 66.7% neutral rating.
Outlook remains positive with expanding profitability and strategic acquisitions, though recent earnings misses and rising debt-to-asset ratio (26.25%) present execution risks. The stock trades at attractive valuations (P/E 12.66, P/B 1.19) but faces integration challenges from Macquarie acquisition and geopolitical uncertainties affecting growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
